DSpace at RU >

Search Results

Results 1-15 of 15.

Item hits:

Full Text	Issue Date	Title	Author(s)
	2010	Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.	Deenik, W.; Janssen, J.J.M.; Holt, B. van der; Verhoef, G.E.; Smit, W.M.; Kersten, M.J.; Daenen, S.M.G.J.; Verdonck, L.F.; Ferrant, A.; Schattenberg, A.V.M.B.; Sonneveld, P.; Marwijk Kooy, M. van; Wittebol, S.; Willemze, R.; Wijermans, P.W.; Beverloo, H.B.; Lowenberg, B.; Valk, P.J.; Ossenkoppele, G.J.; Cornelissen, J.J.
	2009	Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.	Loosdrecht, A.A. van de; Alhan, C.; Bene, M.C.; Porta, M.G. Della; Drager, A.M.; Feuillard, J.; Font, P.; Germing, U.; Haase, D.; Homburg, C.H.; Ireland, R.; Jansen, J.H.; Kern, W.; Malcovati, L.; Marvelde, J.G. Te; Mufti, G.J.; Ogata, K.; Orfao, A.; Ossenkoppele, G.J.; Porwit, A.; Preijers, F.W.M.B.; Richards, S.J.; Schuurhuis, G.J.; Subira, D.; Valent, P.; Velden, V.H. van der; Vyas, P.; Westra, A.H.; Witte, T.J.M. de; Wells, D.A.; Loken, M.R.; Westers, T.M.
	2008	Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.	Deenik, W.; Holt, B. van der; Verhoef, G.E.; Smit, W.M.; Kersten, M.J.; Kluin-Nelemans, H.C.; Verdonck, L.F.; Ferrant, A.; Schattenberg, A.V.M.B.; Janssen, J.J.H.M.; Sonneveld, P.; Kooy, M van Marwijk; Wittebol, S.; Willemze, R.; Wijermans, P.W.; Westveer, P.H.; Beverloo, H.B.; Valk, P. van de; Lowenberg, B.; Ossenkoppele, G.J.; Cornelissen, J.J.L.M.
	2007	Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).	Verdonck, L.F.; Notenboom, A.; Jong, D.D. de; MacKenzie, M.A.; Verhoef, G.E.; Kramer, M.H.; Ossenkoppele, G.J.; Doorduijn, J.K.; Sonneveld, P.; Imhoff, G.W. van
	2007	High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia : A prospective randomized phase III study	Deenik, W.; Holt, B. van der; Verhoef, G.E.; Schattenberg, A.V.M.B.; Verdonck, L.F.; Daenen, S.M.G.J.; Zachee, P.; Westveer, P.H.; Smit, W.M.; Wittebol, S.; Schouten, H.C.; Lowenberg, B.; Ossenkoppele, G.J.; Cornelissen, J.J.L.M.
	2007	Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas.	Muris, J.J.; Ylstra, B.; Cillessen, S.A.; Ossenkoppele, G.J.; Kluin-Nelemans, J.C.; Eijk, P.P.; Nota, B.; Tijssen, M.; Boer, W.P. de; Wiel, M. van de; IJssel, P.R.L.A. van den; Jansen, P.; Bruin, P.C. de; Krieken, J.H.J.M. van; Meijer, G.A.; Meijer, C.J.; Oudejans, J.J.
	2006	Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.	Muris, J.J.; Meijer, C.J.M.; Vos, W.; Krieken, J.H.J.M. van; Jiwa, N.M.; Ossenkoppele, G.J.; Oudejans, J.J.
	2005	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas.	Muris, J.J.; Cillessen, S.A.; Vos, W.; Houdt, I.S. van; Kummer, J.A.; Krieken, J.H.J.M. van; Jiwa, N.M.; Jansen, P.A.M.; Kluin-Nelemans, H.C.; Ossenkoppele, G.J.; Gundy, C.; Meijer, C.J.M.; Oudejans, J.J.
	2005	Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.	Imhoff, G.W. van; Holt, B. van der; MacKenzie, M.A.; Ossenkoppele, G.J.; Wijermans, P.W.; Kramer, M.H.; Veer, M.B. van 't; Schouten, H.C.; Marwijk-Kooy, M. van; Oers, M.H. van; Raemaekers, J.M.M.; Sonneveld, P.; Meulendijks, L.A.; Kluin, P.; Kluin-Nelemans, H.C.; Verdonck, L.F.
	2005	Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.	Imhoff, G.W. van; Holt, B. van der; MacKenzie, M.A.; Veer, M.B. van 't; Wijermans, P.W.; Ossenkoppele, G.J.; Schouten, H.C.; Sonneveld, P.; Steijaert, M.M.; Kluin, P.; Kluin-Nelemans, H.C.; Verdonck, L.F.
	2005	Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.	Straaten, H.M. van der; Biezen, A. van; Brand, R.; Schattenberg, A.V.M.B.; Egeler, R.M.; Barge, R.M.; Cornelissen, J.J.L.M.; Schouten, H.C.; Ossenkoppele, G.J.; Verdonck, L.F.
	2004	Immuno-histochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell	Muris, J.J.; Cillessen, S.A.; Vos, W.K.; Houdt, I.S. van; Kummer, J.A.; Krieken, J.H.J.M. van; Jiwa, N.M.; Jansen, P.A.M.; Kluin-Nelemans, H.C.; Ossenkoppele, G.J.; Gundy, C.; Meijer, C.J.; Oudejans, J.J.
	2004	The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.	Ossenkoppele, G.J.; Graveland, W.J.; Sonneveld, P.; Daenen, S.M.G.J.; Biesma, D.H.; Verdonck, L.F.; Schaafsma, M.R.; Westveer, P.H.; Peters, G.J.; Noordhuis, P.; Muus, P.; Selleslag, D.; Holt, B. van der; Delforge, M.; Lowenberg, B.; Verhoef, G.E.
	2004	Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas	Muris, J.J.; Meijer, C.J.; Cillessen, S.A.; Vos, W.K.; Kummer, J.A.; Bladergroen, B.A.; Bogman, M.J.J.T.; MacKenzie, M.A.; Jiwa, N.M.; Siegenbeek van Heukelom, L.H.; Ossenkoppele, G.J.; Oudejans, J.J.
	1997	Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the research and treatment of cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON)	Lowenberg, B.; Suciu, S.; Archimbaud, E.; Ossenkoppele, G.J.; Verhoef, G.E.G.; Vellenga, E.; Wijermans, P.; Berneman, Z.; Dekker, A.W.; Stryckmans, P.; Schouten, H.C.; Jehn, U.; Muus, P.; Sonneveld, P.; Dardenne, M.; Zittoun, R.

1